Engineered devices and materials of 100 nanometers or less in size are showing potential in the detection, diagnosis, tracking and treatment of cancer. Approaches in nanotechnology applied to major problems in cancer are in their formative stages. The Cancer Nanotechnology Program brings together physicians and scientists from diverse disciplines in the physical and life sciences at UCLA and Caltech, in the common pursuit of improved understanding and outcomes in cancer.
- To provide a cross-disciplinary program that facilitates the development and application of nanotechnology approaches to basic and clinical problems in cancer
- Engineer, test and deliver a wide range of therapeutic anti-cancer nanoparticles
- Develop nanoscale imaging modalities to detect, quantify and track cancers
- Invent and refine custom surface, analytic and manipulative platforms using nanoscale engineering principles
- Translate promising approaches into preclinical model and early phase clinical testing
Meetings and Events
- Quarterly research program scientific exchange dinners
- Invited speakers in the Jonsson Cancer Center, IMED and CNSI seminar series
- Semi-annual, inter-programmatic symposia on Nanotechnology in Cancer
Dr. Dino Di Carlo is director of the Cancer Nanotechnology Program, member of the California NanoSystem Institute at UCLA and associate professor of bioengineering. His research focuses on engineering of microfluidic and nanoparticle systems for the analysis of single cells for both improving cell-based diagnostics and automating cell biology. His group takes advantage of inertial fluid dynamic effects in particular to engineer simple systems for translational applications.
Co-director Dr. James Heath is the E.W. Gilloon Professor of Chemistry at Caltech, and Director of the NanoSystems Biology Cancer Center, a NCI Center for Cancer Nanotechnology Excellence (CCNE). His work has been recognized with the Feynman Prize in Nanotechnology, the Sackler Prize in Physical Sciences, the Doolittle Award, the Spiers Medal of the Royal Society, and he is one of the seven top innovators in the world according to Forbes. He leads a collaborative research program in cancer diagnostics using microfluidic devices, capture agents, single cell secretion systems, tumor hypoxia and protein regulation and dissection of cellular immunity against cancer by highly multiplexed approaches.
The following list is for upcoming events and seminars of notable interest to the Cancer Nanotechnology Program and its members. This calendar is updated automatically.
For a list of all upcoming JCCC events (including other research programs, patients and survivors, and the UCLA Jonsson Cancer Center Foundation), please visit the Events Calendar.